AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3661610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g suspension four times daily for eight weeks
Number of subjects: 42
Study 3661610 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg four times daily for eight weeks
Number of subjects: 42
Study 31912660 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 96
Study 31912660 — intervention group
Group type: COMPARATOR
Intervention: FS-LASIK
Number of subjects: 96
Study 29452589 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (G1)
Number of subjects: 608
Study 29452589 — intervention group
Group type: EXPERIMENTAL
Intervention: Web + e-mail intervention (G2)
Number of subjects: 608
Study 29452589 — intervention group
Group type: EXPERIMENTAL
Intervention: Web + SMS intervention (G3)
Number of subjects: 608
Study 27624835 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive payments with audit plus feedback
Number of subjects: 0
Study 27624835 — intervention group
Group type: COMPARATOR
Intervention: Financial incentive payments without audit plus feedback
Number of subjects: 0
Study 27624835 — intervention group
Group type: COMPARATOR
Intervention: Audit plus feedback without financial incentive payments
Number of subjects: 0
Study 27624835 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive payments and no audit plus feedback
Number of subjects: 0
Study 25277496 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 0
Study 25277496 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 0
Study 22429969 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (epinephrine)
Number of subjects: 174
Study 22429969 — intervention group
Group type: COMPARATOR
Intervention: No adrenaline
Number of subjects: 174
Study 20831680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 473
Study 20831680 — intervention group
Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 473
Study 18224352 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular approach (TM) with expandable tubular retractor
Number of subjects: 125
Study 18224352 — intervention group
Group type: COMPARATOR
Intervention: Subperiosteal approach (SP) with speculum-counter-retractor
Number of subjects: 125
Study 16325039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 40
Study 16325039 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 12570120 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 730
Study 12570120 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (200 microg twice daily)
Number of subjects: 730
Study 12570120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 12570120 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 730
Study 12570120 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 730
Study 10671811 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancies
Number of subjects: 50
Study 10671811 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed abortions
Number of subjects: 50
Study 10671811 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pregnancies and missed abortions
Number of subjects: 50
Study 8895621 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical closure in flexion (90 to 110 degrees)
Number of subjects: 108
Study 8895621 — intervention group
Group type: COMPARATOR
Intervention: Surgical closure in extension
Number of subjects: 108
Study 1382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (63 pmol)
Number of subjects: 0
Study 1382539 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic
Number of subjects: 0
Study 1382539 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin pretreatment
Number of subjects: 0
Study 1382539 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (10 mg orally, 4 h before injection)
Number of subjects: 0
Study 1382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (0.3-10 microM)
Number of subjects: 0
Study 1382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol (1-30 microM)
Number of subjects: 0
Study 3988974 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg/day for 6 weeks
Number of subjects: 83
Study 29746294 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day per week Atripla regimen (3W)
Number of subjects: 61
Study 29746294 — intervention group
Group type: COMPARATOR
Intervention: Once daily Atripla regimen (OD)
Number of subjects: 61
Study 27485727 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified advance notification letter
Number of subjects: 9216
Study 27485727 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation material (control group)
Number of subjects: 9216
Study 27485727 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified invitation letter
Number of subjects: 9216
Study 26352144 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐HRCT scanner (0.25 mm x 4 rows, 120 mAs)
Number of subjects: 37
Study 26352144 — intervention group
Group type: COMPARATOR
Intervention: C‐HRCT scanner (0.5 mm x 16 or 0.5 mm x 64 rows, 150 mAs)
Number of subjects: 37
Study 26352144 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐HRCT scanner
Number of subjects: 37
Study 26352144 — intervention group
Group type: COMPARATOR
Intervention: C‐HRCT scanner
Number of subjects: 37
Study 23924587 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir (ADV) therapy
Number of subjects: 17
Study 23924587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21668806 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 20
Study 21668806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18195173 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 0.20 mg/kg/day
Number of subjects: 116
Study 18195173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 16774980 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.0-3.0)
Number of subjects: 2257
Study 16774980 — intervention group
Group type: COMPARATOR
Intervention: Ximelagatran (36 mg twice daily)
Number of subjects: 2257
Study 16774980 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2257
Study 12509377 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions used to promote patient recruitment
Number of subjects: 6070
Study 12509377 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational characteristics
Number of subjects: 6070
Study 12509377 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 'favourable' organizational characteristics
Number of subjects: 6070
Study 11092064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 2‐mg sublingual tablet
Number of subjects: 247
Study 11092064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 8973871 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 101
Study 8973871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 8973871 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RA
Number of subjects: 101
Study 1534211 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 3 mg/kg
Number of subjects: 23
Study 1534211 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 12 mg/kg
Number of subjects: 23
Study 1534211 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 30 mg/kg
Number of subjects: 23
Study 1534211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of all doses (3, 12, 30 mg/kg)
Number of subjects: 23
Study 6330886 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 0
Study 6330886 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 0
Study 6330886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ranitidine and famotidine
Number of subjects: 0
Study 6330886 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day famotidine treatment
Number of subjects: 0
Study 28810429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain sensitivity
Number of subjects: 0
Study 28810429 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared human alarm system of unfairness and pain sensitivity
Number of subjects: 0
Study 29800211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly dosing (225 mg at baseline, week 4, and week 8)
Number of subjects: 875
Study 29800211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab single higher dose (675 mg at baseline; placebo at weeks 4 and 8)
Number of subjects: 875
Study 29800211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (at baseline, week 4, and week 8)
Number of subjects: 875
Study 26294680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based program once a week for 6 weeks
Number of subjects: 296
Study 26294680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based program twice a week for 6 weeks
Number of subjects: 296
Study 26294680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based program three times a week for 6 weeks
Number of subjects: 296
Study 26294680 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet only (control group)
Number of subjects: 296
Study 24478399 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12
Study 24478399 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion during clamp
Number of subjects: 12
Study 24478399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid/heparin mixture
Number of subjects: 12
Study 24478399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22441580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrotherapy (LFE) for normal compliance (LFE-NC)
Number of subjects: 102
Study 22441580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrotherapy (LFE) for low compliance (LFE-LC)
Number of subjects: 102
Study 22441580 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for normal compliance (CON-NC)
Number of subjects: 102
Study 22441580 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for low compliance (CON-LC)
Number of subjects: 102
Study 21067061 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 28
Study 17362728 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzer solution
Number of subjects: 51
Study 17362728 — intervention group
Group type: COMPARATOR
Intervention: Custodiol solution
Number of subjects: 51
Study 16248984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (60mg/day for 4 weeks)
Number of subjects: 21
Study 12271807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus routine care
Number of subjects: 315
Study 12271807 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling plus routine care
Number of subjects: 315
Study 12271807 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 315
Study 10414537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-laparoscopic cholecystectomy (mini-LC)
Number of subjects: 200
Study 10414537 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (C-LC)
Number of subjects: 200
Study 10414537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (mini-LC and C-LC)
Number of subjects: 200
Study 8789468 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (COMB-HC)
Number of subjects: 20
Study 8789468 — intervention group
Group type: COMPARATOR
Intervention: Standard circuits (COMB-C)
Number of subjects: 20
Study 8789468 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (CABG-HC)
Number of subjects: 20
Study 8789468 — intervention group
Group type: COMPARATOR
Intervention: Standard circuits (CABG-C)
Number of subjects: 20
Study 1498296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.15 mg/kg bolus followed by 2 micrograms/kg/min)
Number of subjects: 29
Study 1498296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1498296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 29
Study 6366822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 30
Study 6366822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 30
Study 6366822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 30
Study 6366822 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 30
Study 6366822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30667502 — intervention group
Group type: EXPERIMENTAL
Intervention: Low free sugar diet (restricted to less than 3% of daily calories for 8 weeks)
Number of subjects: 40
Study 30667502 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (participants consumed their regular diet)
Number of subjects: 40
Study 30667502 — intervention group
Group type: EXPERIMENTAL
Intervention: Low free sugar diet
Number of subjects: 40
Study 30667502 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 40
Study 29127945 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 95
Study 29127945 — intervention group
Group type: COMPARATOR
Intervention: CBM-I
Number of subjects: 95
Study 29127945 — intervention group
Group type: COMPARATOR
Intervention: Combined ABMT + CBM-I
Number of subjects: 95
Study 29127945 — intervention group
Group type: COMPARATOR
Intervention: Combined control
Number of subjects: 95
Study 27640607 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen plus oxycodone/acetaminophen
Number of subjects: 0
Study 27640607 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen plus cyclobenzaprine
Number of subjects: 0
Study 27640607 — intervention group
Group type: COMPARATOR
Intervention: naproxen plus placebo
Number of subjects: 0
Study 24528604 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) for elderly patients
Number of subjects: 62
Study 24528604 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 62
Study 22920800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin + recombinant human hyaluronidase (rHuPH20)
Number of subjects: 60000
Study 22920800 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of rapid-acting insulin + rHuPH20
Number of subjects: 60000
Study 22920800 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of rapid-acting insulin + rHuPH20
Number of subjects: 60000
Study 21056840 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture and behavior therapy
Number of subjects: 180
Study 21056840 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture and behavior therapy
Number of subjects: 180
Study 17380679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 360
Study 17380679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 360
Study 17380679 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 360
Study 15797276 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Rule (CDR) for identifying pulmonary embolism (PE) as a cause of cardiac arrest
Number of subjects: 44
Study 15797276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-arrest clinical triad of respiratory distress, altered mental status, and shock
Number of subjects: 44
Study 15797276 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessed arrests by EMS or ED physicians
Number of subjects: 44
Study 12015525 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 130
Study 12015525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 130
Study 12015525 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 130
Study 12015525 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 130
Study 10535857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg + Vitamin E 100 mg twice daily
Number of subjects: 145
Study 8584522 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg Fenoterol
Number of subjects: 15
Study 8584522 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg Salbutamol
Number of subjects: 15
Study 8584522 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg Salmeterol
Number of subjects: 15
Study 8584522 — intervention group
Group type: COMPARATOR
Intervention: Rescue medication (Salbutamol MDI)
Number of subjects: 15
Study 2338888 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg/h for 4 h)
Number of subjects: 12
Study 2338888 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 6116950 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study 6116950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 30728064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led web-based intervention to promote safe usage of dating applications
Number of subjects: 338
Study 30728064 — intervention group
Group type: COMPARATOR
Intervention: Web-based resource on health and exercise (Control)
Number of subjects: 338
Study 27770498 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treadmill running session
Number of subjects: 40
Study 27770498 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term individual shear rate therapy (ISRT)
Number of subjects: 40
Study 26578736 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 400 mg/day plus metformin 750-2250 mg/day for 24-36 weeks
Number of subjects: 36
Study 24948402 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine (maximal dose 20 mg/day)
Number of subjects: 60
Study 24948402 — intervention group
Group type: EXPERIMENTAL
Intervention: dextromethorphan (maximal dose 90 mg/day)
Number of subjects: 60
Study 24948402 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 24948402 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 60
Study 24948402 — intervention group
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Number of subjects: 60
Study 22271868 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training
Number of subjects: 10
Study 22271868 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological inhibition of NO and prostanoid systems
Number of subjects: 10
Study 22271868 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine-induced response
Number of subjects: 10
Study 19934286 — intervention group
Group type: EXPERIMENTAL
Intervention: CH4987655 (0.5, 1, 2, 3, and 4 mg)
Number of subjects: 40
Study 18062141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil vaccine
Number of subjects: 0
Study 18062141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Number of subjects: 0
Study 18062141 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15279530 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal classroom-based intervention
Number of subjects: 0
Study 11437394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IM Medroxyprogesterone acetate (HD-MPA) adjuvant hormonotherapy during 6 months
Number of subjects: 516
Study 11437394 — intervention group
Group type: COMPARATOR
Intervention: No hormonotherapy
Number of subjects: 516
Study 9544333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride injection with heparin sodium 10 units/mL
Number of subjects: 58
Study 9544333 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection without heparin sodium
Number of subjects: 58
Study 7916540 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment of Negative Symptoms
Number of subjects: 207
Study 3385897 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational work evaluation (n = 99)
Number of subjects: 201
Study 3385897 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 102)
Number of subjects: 201
Study 29518178 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 300 mg IV every 12 hours for 3 days followed by 450 mg oral delafloxacin
Number of subjects: 850
Study 29518178 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg IV with aztreonam for 5-14 days
Number of subjects: 850
Study 29518178 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 850
Study 29518178 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin + aztreonam
Number of subjects: 850
Study 28460260 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 394
Study 28460260 — intervention group
Group type: COMPARATOR
Intervention: Limited screening
Number of subjects: 394
Study 26775477 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Activating Wind Dissipating Acupuncture (BAWDA) for 6 weeks (30 sessions)
Number of subjects: 60
Study 26775477 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Activating Wind Dissipating Acupuncture (BAWDA)
Number of subjects: 60
Study 23749688 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week supervised aerobic exercise training (twice weekly)
Number of subjects: 43
Study 23749688 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 20970119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 706
Study 20970119 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 706
Study 20970119 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for mice)
Number of subjects: 706
Study 19930864 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and brief intervention (SBI)
Number of subjects: 0